In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS

 

Assessment of motion correction on myocardial blood flow from dynamic rubidium-82 PET

Session Poster session III

Speaker Matthew Memmott

Congress : ICNC, Nuclear Cardiology & Cardiac CT 2019

  • Topic : imaging
  • Sub-topic : Positron Emission Tomography (PET)
  • Session type : Poster Session
  • FP Number : P396

Authors : IS Armstrong (Manchester,GB), MJ Memmott (Manchester,GB), KJ Saint (Manchester,GB), A Saillant (Knoxville,US), C Hayden (Knoxville,US), P Arumugam (Manchester,GB)

Authors:
IS Armstrong1 , MJ Memmott1 , KJ Saint1 , A Saillant2 , C Hayden2 , P Arumugam1 , 1Manchester University NHS Foundation Trust - Manchester - United Kingdom of Great Britain & Northern Ireland , 2Siemens Medical Solutions USA, Inc., Molecular Imaging - Knoxville - United States of America ,

On behalf: Manchester

Citation:

Introduction
Myocardial blood flow (MBF) has proven additive value in rubidium-82 cardiac PET. However, non-periodic patient motion, as a result of the side-effects of pharmacological stressing, can have substantial impact on MBF data. This work evaluated frame-by-frame motion correction both with and without corresponding adjustment of the PET attenuation map.

Method
Frame-by-frame translational motion correction was performed by three experienced users on 30 rubidium-82 studies. Data were divided equally into 3 groups of motion severity [mild (M1), moderate (M2) and severe (M3)]. MBF data were generated in syngo.PET MBF (Siemens Healthineers) for non-motion-corrected (NC), motion-corrected only (MC) and motion-corrected with corresponding adjustment of the attenuation map (MCAC). MCAC were generated with prototype reconstruction software (e7 tools, Siemens Healthineers). Percentage differences of MBF were calculated in the three coronary territories and also in 17-segment polar plots. 17-segment polar plots of spill-over values, obtained from Syngo.PET MBF, were also generated for NC, MC and MCAC data.

Results
The table shows the median and inter-quartile range of absolute percentage change of MBF for the three motion categories for MC compared with NC data. In the 17-segment polar maps, median MBF differences of up to 50% were observed in the mid-anterior segment and up to 30% in the mid-inferior segment for MC vs NC. Median segmental differences for MCAC compared with MC were considerably smaller with a maximum of 15%. Segmental plots of median spill-over values were notably more uniform for MC and MCAC data compared with NC data.

Conclusion
Motion correction results in substantial adjustments to MBF data, highlighting the need for readily available robust motion correction techniques. Frame-by-frame adjustment of the attenuation map results in marginal differences and therefore is unlikely to be an essential requirement. This is fortunate as it involves close integration into the PET reconstruction and is not currently available commercially. Assessing the uniformity of spill-over plots post-correction is a useful visual aid for verifying both manual and automated motion correction techniques.

LAD LCX RCA
M1 M2 M3 M1 M2 M3 M1 M2 M3
Q1 1% 2% 7% 2% 4% 2% 5% 7% 14%
Median 4% 6% 18% 4% 6% 9% 10% 13% 23%
Q3 10% 17% 26% 8% 15% 14% 16% 25% 34%
Median and inter-quartile range for absolute percentage changes to MBF for MC data compared with NC data.

This content is currently on FREE ACCESS

 



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are